Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.06) by 76.67 percent. This is a 960 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $86.70 million which missed the analyst consensus estimate of $90.77 million by 4.48 percent. This is a 21.16 percent decrease over sales of $109.98 million the same period last year.